Liver and haematological safety of sulfadoxine-pyrimethamine treatment in non-complicated falciparum malaria.
Article Sidebar
Main Article Content
Introduction: Sulfadoxine-pyrimethamine is an antimalarial used currently in worldwide for non-complicated falciparum malaria. This drug is administrated in combination with other ones. Previously adverse events had been reported with high doses, used in malaria prophylaxis and patients with hypersensibility to sulfas.
Objetive: To evaluate hepatic and haematic toxicity of treatment with sulfadoxine-pyrimethamine (SP) in non-complicated falciparum malaria.
Methodology: This was a non-blinded experimental design. In Turbo (Antioquia, Colombia), 17 subjects treated with SP were evaluated for liver and hematic function. All individual were followed for 10 days.
Results: Before treatment, liver and hematic function tests were slight altedered. Hematic and liver variables returned to physiological levels after treatment. Treatment had 100% efficacy. All tests were within normal levels throughout the following period (postreatment); this suggests absence of toxic effects associates with treatment. Adverse effects were few and slight, and disappeared on day-10.
Conclusions: When is used in time and dose for treatment of non-complicated falciparum malaria, SP neither increased adverse events nor hepatic or hematic toxicity.
Objetive: To evaluate hepatic and haematic toxicity of treatment with sulfadoxine-pyrimethamine (SP) in non-complicated falciparum malaria.
Methodology: This was a non-blinded experimental design. In Turbo (Antioquia, Colombia), 17 subjects treated with SP were evaluated for liver and hematic function. All individual were followed for 10 days.
Results: Before treatment, liver and hematic function tests were slight altedered. Hematic and liver variables returned to physiological levels after treatment. Treatment had 100% efficacy. All tests were within normal levels throughout the following period (postreatment); this suggests absence of toxic effects associates with treatment. Adverse effects were few and slight, and disappeared on day-10.
Conclusions: When is used in time and dose for treatment of non-complicated falciparum malaria, SP neither increased adverse events nor hepatic or hematic toxicity.
- Malaria
- Plasmodium falciparum
- Sulfadoxine-pyrimethamine
- Amodiaquine
- Toxicity
Carmona Fonseca, J., López, M. L., & Piñeros, J. G. (2008). Liver and haematological safety of sulfadoxine-pyrimethamine treatment in non-complicated falciparum malaria. Colombia Medica, 39(3), 235–244. https://doi.org/10.25100/cm.v39i3.591
Downloads
Download data is not yet available.
- Jaime Carmona Fonseca, Rosa M. Uscátegui, Adriana María Correa, Vivax malaria in children: clinical features and response to chloroquine. , Colombia Medica: Vol. 39 No. 4 (2008)
- Jaime Carmona Fonseca, Valentina Guzmán Pérez, Amanda Maestre Buitrago, Malaria: efficacy of amodiaquine-sulfadoxine-pyrimethamine, nutritional status and alellic variaton of CYP2C8 gen , Colombia Medica: Vol. 40 No. 1 (2009)
- Juan Gabriel Piñeros, Mary Luz López, Jaime Carmona Fonseca, Silvia Blair, Liver and haematological safety of amodiaquine treatment in non-complicated falciparum malaria. , Colombia Medica: Vol. 37 No. 4 (2006)
The copy rights of the articles published in Colombia Médica belong to the Universidad del Valle. The contents of the articles that appear in the Journal are exclusively the responsibility of the authors and do not necessarily reflect the opinions of the Editorial Committee of the Journal. It is allowed to reproduce the material published in Colombia Médica without prior authorization for non-commercial use